Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:BCEL

Atreca (BCEL) Stock Price, News & Analysis

Atreca logo

About Atreca Stock (NASDAQ:BCEL)

Key Stats

Today's Range
$0.09
$0.09
50-Day Range
$0.09
$0.09
52-Week Range
$0.05
$1.20
Volume
N/A
Average Volume
4.61 million shs
Market Capitalization
$3.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

BCEL Stock News Headlines

Six Stocks That Could Soar on Trump’s First Day Back
The recent election results have clarified a path forward, creating opportunities that weren't as clear just months ago. Louis has identified six specific AI stocks that are poised to benefit from this.
Atreca, Inc. (0C1.MU)
Atreca Inc. Cl A
Atreca Stock (NASDAQ:BCEL), Short Interest Report
See More Headlines

BCEL Stock Analysis - Frequently Asked Questions

Atreca, Inc. (NASDAQ:BCEL) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.74).

Atreca (BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atreca investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alector (ALEC), Advanced Micro Devices (AMD), PayPal (PYPL) and Meta Platforms (META).

Company Calendar

Last Earnings
11/02/2021
Today
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCEL
Fax
N/A
Employees
130
Year Founded
N/A

Profitability

Net Income
$-97,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.01 per share

Miscellaneous

Free Float
35,146,000
Market Cap
$3.57 million
Optionable
Optionable
Beta
1.03
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:BCEL) was last updated on 12/24/2024 by MarketBeat.com Staff
From Our Partners